Scinai Immunotherapeutics Past Earnings Performance
Past criteria checks 0/6
Scinai Immunotherapeutics has been growing earnings at an average annual rate of 38%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 109.1% per year.
Key information
38.0%
Earnings growth rate
63.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 109.1% |
| Return on equity | n/a |
| Net Margin | -1,304.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10
Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering
Jan 29Revenue & Expenses Breakdown
How Scinai Immunotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -4 | 3 | 5 |
| 31 Mar 24 | 0 | -5 | 4 | 5 |
| 31 Dec 23 | 0 | -6 | 5 | 5 |
| 30 Sep 23 | 0 | -9 | 5 | 6 |
| 30 Jun 23 | 0 | -8 | 5 | 6 |
| 31 Mar 23 | 0 | -7 | 5 | 7 |
| 31 Dec 22 | 0 | -6 | 5 | 6 |
| 30 Sep 22 | 0 | -8 | 5 | 5 |
| 30 Jun 22 | 0 | -8 | 7 | 5 |
| 31 Mar 22 | 0 | -8 | 8 | 4 |
| 31 Dec 21 | 0 | -8 | 8 | 3 |
| 30 Sep 21 | 0 | -13 | 7 | 5 |
| 30 Jun 21 | 0 | 6 | 7 | 8 |
| 31 Mar 21 | 0 | -3 | 6 | 11 |
| 31 Dec 20 | 0 | -1 | 5 | 16 |
| 30 Sep 20 | 0 | -10 | 4 | 22 |
| 30 Jun 20 | 0 | -31 | 3 | 23 |
| 31 Mar 20 | 0 | -32 | 3 | 23 |
| 31 Dec 19 | 0 | -32 | 3 | 20 |
| 30 Sep 19 | 0 | -32 | 3 | 18 |
| 30 Jun 19 | 0 | -25 | 2 | 15 |
| 31 Mar 19 | 0 | -20 | 2 | 18 |
| 31 Dec 18 | 0 | -23 | 1 | 19 |
| 30 Sep 18 | 0 | -15 | 1 | 16 |
| 30 Jun 18 | 0 | -15 | 2 | 15 |
| 31 Mar 18 | 0 | -11 | 1 | 8 |
| 31 Dec 17 | 0 | -10 | 1 | 5 |
| 30 Sep 17 | 0 | -7 | 1 | 2 |
| 30 Jun 17 | 0 | -8 | 1 | 2 |
| 31 Mar 17 | 0 | -5 | 1 | 2 |
| 31 Dec 16 | 0 | -2 | 1 | 2 |
| 30 Sep 16 | 0 | -3 | 1 | 2 |
| 30 Jun 16 | 0 | -2 | 1 | 2 |
| 31 Mar 16 | 0 | -3 | 1 | 2 |
| 31 Dec 15 | 0 | -3 | 1 | 2 |
| 30 Sep 15 | 0 | -2 | 1 | 2 |
| 30 Jun 15 | 0 | -3 | 1 | 2 |
| 31 Mar 15 | 0 | -2 | 1 | 1 |
| 31 Dec 14 | 0 | -2 | 1 | 1 |
| 30 Sep 14 | 0 | -2 | 1 | 2 |
| 30 Jun 14 | 0 | -2 | 1 | 2 |
| 31 Mar 14 | 0 | -2 | 1 | 2 |
Quality Earnings: SCNI is currently unprofitable.
Growing Profit Margin: SCNI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCNI is unprofitable, but has reduced losses over the past 5 years at a rate of 38% per year.
Accelerating Growth: Unable to compare SCNI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCNI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SCNI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.